Online inquiry

IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8053MR)

This product GTTS-WQ8053MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8053MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7246MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ3773MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ11809MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ12109MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ5538MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ11208MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ9977MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ8583MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW